-
Something wrong with this record ?
Pyrazine derivatives: a patent review (June 2012 - present)
M. Dolezal, J. Zitko,
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
- MeSH
- Alzheimer Disease drug therapy enzymology MeSH
- Drug Industry legislation & jurisprudence MeSH
- Protein Kinase Inhibitors pharmacology MeSH
- Humans MeSH
- Molecular Structure MeSH
- Neuroprotective Agents pharmacology MeSH
- Patents as Topic * MeSH
- Cell Proliferation drug effects MeSH
- Pyrazines chemistry pharmacology therapeutic use MeSH
- Drug Design MeSH
- Amyloid Precursor Protein Secretases antagonists & inhibitors metabolism MeSH
- Structure-Activity Relationship MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
INTRODUCTION: Pyrazine is a member of 1,4-diazines, which constitute an important class of heterocycles. Various pyrazine derivatives have been synthesized and successfully evaluated as agents with diverse pharmacological effects (including but not limited to antiproliferative, anti-infective, and effects on cardiovascular or nervous system) and some of them have become clinically used drugs worldwide. AREA COVERED: This review is a survey of important patents on pyrazine derivatives with pharmacological activity published in the period June 2012 - July 2014. The patent databases SciFinder and esp@cenet were used to locate patent applications. EXPERT OPINION: Pyrazine derivatives possess numerous noteworthy pharmacological effects, including antimycobacterial, antibacterial, antifungal, antidiabetic, diuretic, anticancer, antiviral, hypnotic, and analgesic. The class of pyrazine-based candidate drugs has experienced a rapid growth both in absolute numbers of investigated compounds and in the spectrum of diverse biological activities. We expect that several of these compounds will add to existing pharmaceuticals in the very near future. According to the number of compounds and filed patents, the most promising areas are: i) inhibitors of protein kinases (applicable as antiproliferatives); and ii) inhibitors of β-secretase (applicable for the treatment of Alzheimer's disease).
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15031577
- 003
- CZ-PrNML
- 005
- 20151012102348.0
- 007
- ta
- 008
- 151005s2015 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1517/13543776.2014.982533 $2 doi
- 035 __
- $a (PubMed)25523365
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Dolezal, Martin $u Charles University in Prague, Faculty of Pharmacy in Hradec Kralove , Heyrovskeho 1203, 50005 Hradec Kralove , Czech Republic.
- 245 10
- $a Pyrazine derivatives: a patent review (June 2012 - present) / $c M. Dolezal, J. Zitko,
- 520 9_
- $a INTRODUCTION: Pyrazine is a member of 1,4-diazines, which constitute an important class of heterocycles. Various pyrazine derivatives have been synthesized and successfully evaluated as agents with diverse pharmacological effects (including but not limited to antiproliferative, anti-infective, and effects on cardiovascular or nervous system) and some of them have become clinically used drugs worldwide. AREA COVERED: This review is a survey of important patents on pyrazine derivatives with pharmacological activity published in the period June 2012 - July 2014. The patent databases SciFinder and esp@cenet were used to locate patent applications. EXPERT OPINION: Pyrazine derivatives possess numerous noteworthy pharmacological effects, including antimycobacterial, antibacterial, antifungal, antidiabetic, diuretic, anticancer, antiviral, hypnotic, and analgesic. The class of pyrazine-based candidate drugs has experienced a rapid growth both in absolute numbers of investigated compounds and in the spectrum of diverse biological activities. We expect that several of these compounds will add to existing pharmaceuticals in the very near future. According to the number of compounds and filed patents, the most promising areas are: i) inhibitors of protein kinases (applicable as antiproliferatives); and ii) inhibitors of β-secretase (applicable for the treatment of Alzheimer's disease).
- 650 _2
- $a Alzheimerova nemoc $x farmakoterapie $x enzymologie $7 D000544
- 650 _2
- $a sekretasy $x antagonisté a inhibitory $x metabolismus $7 D053829
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a proliferace buněk $x účinky léků $7 D049109
- 650 _2
- $a racionální návrh léčiv $7 D015195
- 650 _2
- $a farmaceutický průmysl $x zákonodárství a právo $7 D004345
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a neuroprotektivní látky $x farmakologie $7 D018696
- 650 12
- $a patenty jako téma $7 D010330
- 650 _2
- $a inhibitory proteinkinas $x farmakologie $7 D047428
- 650 _2
- $a pyraziny $x chemie $x farmakologie $x terapeutické užití $7 D011719
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Zitko, Jan
- 773 0_
- $w MED00181402 $t Expert opinion on therapeutic patents $x 1744-7674 $g Roč. 25, č. 1 (2015), s. 33-47
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25523365 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20151005 $b ABA008
- 991 __
- $a 20151012102537 $b ABA008
- 999 __
- $a ok $b bmc $g 1092453 $s 914703
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 25 $c 1 $d 33-47 $i 1744-7674 $m Expert opinion on therapeutic patents $n Expert Opin Ther Pat $x MED00181402
- LZP __
- $a Pubmed-20151005